FR24C1008I1 - Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire - Google Patents

Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Info

Publication number
FR24C1008I1
FR24C1008I1 FR24C1008C FR24C1008C FR24C1008I1 FR 24C1008 I1 FR24C1008 I1 FR 24C1008I1 FR 24C1008 C FR24C1008 C FR 24C1008C FR 24C1008 C FR24C1008 C FR 24C1008C FR 24C1008 I1 FR24C1008 I1 FR 24C1008I1
Authority
FR
France
Prior art keywords
antibodies against
tissue factor
pathway inhibitor
against tissue
factor pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1008C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of FR24C1008I1 publication Critical patent/FR24C1008I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR24C1008C 2008-12-22 2024-02-26 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire Active FR24C1008I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172520 2008-12-22
EP09793543.1A EP2379600B2 (fr) 2008-12-22 2009-12-18 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire
PCT/EP2009/067598 WO2010072691A1 (fr) 2008-12-22 2009-12-18 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Publications (1)

Publication Number Publication Date
FR24C1008I1 true FR24C1008I1 (fr) 2024-04-19

Family

ID=40639722

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1008C Active FR24C1008I1 (fr) 2008-12-22 2024-02-26 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Country Status (19)

Country Link
US (5) US8361469B2 (fr)
EP (3) EP3260466A1 (fr)
JP (2) JP5714505B2 (fr)
KR (2) KR101600308B1 (fr)
CN (1) CN102325795B (fr)
AU (1) AU2009331570C1 (fr)
BR (1) BRPI0924058B1 (fr)
CA (1) CA2745317C (fr)
DK (1) DK2379600T4 (fr)
ES (1) ES2458665T5 (fr)
FR (1) FR24C1008I1 (fr)
IL (1) IL213356A (fr)
MX (1) MX2011006501A (fr)
PL (1) PL2379600T5 (fr)
PT (1) PT2379600E (fr)
RU (1) RU2562114C2 (fr)
TW (1) TWI476003B (fr)
WO (1) WO2010072691A1 (fr)
ZA (1) ZA201104599B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297203A1 (fr) 2008-06-30 2011-03-23 Novo Nordisk A/S Anticorps anti-interleukine-20 humaine
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
PL2379600T5 (pl) * 2008-12-22 2021-03-08 Novo Nordisk A/S Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
RS61082B1 (sr) * 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
EP2542257B1 (fr) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimisation d'anticorps monoclonaux dirigés contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
CN103080135B (zh) * 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
HUE042706T2 (hu) * 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
WO2014015133A1 (fr) 2012-07-19 2014-01-23 National Cheng Kung University Traitement de l'ostéoarthrite au moyen d'antagonistes d'il-20
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6454678B2 (ja) * 2013-03-15 2019-01-16 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ ｐＨ範囲で結合性が異なる薬物動態改善のための抗ＴＦＰＩ抗体変異体
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2014144689A1 (fr) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Anticorps de promédicament dirigés contre l'inhibiteur de la voie du facteur tissulaire
CN105473619B (zh) 2013-07-19 2020-12-15 诺和诺德股份有限公司 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
CN114621346A (zh) 2013-08-21 2022-06-14 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
EA035037B1 (ru) * 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
MD20160130A2 (ro) * 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Anticorpi umanizaţi contra CEACAM1
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
WO2016137108A1 (fr) * 2015-02-25 2016-09-01 Mogam Biotechnology Institute Nouvel anticorps se liant à la tfpi et composition le comprenant
MY195443A (en) * 2015-08-19 2023-01-21 Pfizer Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
JP7094722B2 (ja) * 2018-02-28 2022-07-04 キヤノン株式会社 画像読取装置及び画像形成装置
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
WO2020075083A1 (fr) * 2018-10-11 2020-04-16 Pfizer Inc. Schéma posologique pour des antagonistes du tfpi
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
MX2022005836A (es) * 2019-11-13 2022-06-09 Pfizer Formulacion estable de anticuerpos acuosos.
CA3184718A1 (fr) * 2020-07-02 2022-01-06 Lei Wang Anticorps anti-fxi/fxia, fragment de liaison a l'antigene de celui-ci et utilisation pharmaceutique de celui-ci
US20230357432A1 (en) 2020-09-24 2023-11-09 Novo Nordisk Health A/S Pharmaceutical formulation of concizumab and method of production thereof
WO2023143559A1 (fr) * 2022-01-30 2023-08-03 Westlake University Polypeptides de liaison à tfpi et leurs utilisations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
EP0539975A1 (fr) † 1991-10-31 1993-05-05 Teijin Limited Méthode pour le dosage immunologique de l'inhibiteur de coagulation libre associé à lipoprotéins (LACI) et trousse à cet effet
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
JPH06153981A (ja) 1992-11-30 1994-06-03 Teijin Ltd Ｌａｃｉの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
WO1998048837A1 (fr) 1997-04-30 1998-11-05 Enzon, Inc. Polypeptides a chaine unique modifies par oxyde de polyalkylene
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
US7585842B2 (en) 2004-04-16 2009-09-08 The Reagents Of The University Of California Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7015746B1 (en) * 2004-05-06 2006-03-21 National Semiconductor Corporation Bootstrapped bias mixer with soft start POR
EP1869082B1 (fr) † 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Modulateur de coagulation et de cascades fibrinolytiques
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
DK2379096T3 (da) * 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
US8618263B2 (en) * 2008-12-22 2013-12-31 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (TFPI)
PL2379600T5 (pl) 2008-12-22 2021-03-08 Novo Nordisk A/S Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego
US8965454B2 (en) 2009-03-04 2015-02-24 Andrew Llc Amplifier system for cell sites and other suitable applications
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CN102869385A (zh) 2009-08-18 2013-01-09 巴克斯特国际公司 针对组织因子途径抑制物的适体和其作为出血病症治疗剂的用途
EP2542257B1 (fr) † 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimisation d'anticorps monoclonaux dirigés contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
US8598008B2 (en) † 2010-10-20 2013-12-03 Texas Instruments Incorporated Stacked ESD clamp with reduced variation in clamp voltage
CA2827160A1 (fr) † 2011-02-11 2012-08-16 Baxter Healthcare S.A. Aptameres se liant a l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme produits therapeutiques des troubles hemostatiques
HUE042706T2 (hu) † 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
WO2013142153A2 (fr) † 2012-03-22 2013-09-26 Baxter International Inc. Aptamères pour l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme agents thérapeutiques contre un trouble hémorragique
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2016137108A1 (fr) † 2015-02-25 2016-09-01 Mogam Biotechnology Institute Nouvel anticorps se liant à la tfpi et composition le comprenant
MY195443A (en) † 2015-08-19 2023-01-21 Pfizer Tissue Factor Pathway Inhibitor Antibodies and uses Thereof

Also Published As

Publication number Publication date
JP2012513377A (ja) 2012-06-14
US20110318356A1 (en) 2011-12-29
US20170114147A1 (en) 2017-04-27
KR20160031028A (ko) 2016-03-21
ZA201104599B (en) 2012-03-28
TWI476003B (zh) 2015-03-11
AU2009331570A1 (en) 2011-06-30
CA2745317A1 (fr) 2010-07-01
PT2379600E (pt) 2014-04-29
CN102325795B (zh) 2015-03-25
IL213356A (en) 2017-06-29
RU2562114C2 (ru) 2015-09-10
EP2746294A2 (fr) 2014-06-25
JP2015178495A (ja) 2015-10-08
RU2011129068A (ru) 2013-01-27
US20130251721A1 (en) 2013-09-26
EP3260466A1 (fr) 2017-12-27
US8361469B2 (en) 2013-01-29
AU2009331570C1 (en) 2024-04-18
EP2379600A1 (fr) 2011-10-26
ES2458665T3 (es) 2014-05-06
ES2458665T5 (es) 2021-06-30
EP2379600B1 (fr) 2014-01-22
JP6114326B2 (ja) 2017-04-12
CN102325795A (zh) 2012-01-18
KR101745394B1 (ko) 2017-06-09
DK2379600T4 (da) 2021-01-04
EP2379600B2 (fr) 2020-10-14
CA2745317C (fr) 2019-03-05
BRPI0924058B1 (pt) 2021-08-17
JP5714505B2 (ja) 2015-05-07
BRPI0924058A2 (pt) 2019-10-15
TW201026330A (en) 2010-07-16
DK2379600T3 (da) 2014-04-28
KR20110103432A (ko) 2011-09-20
PL2379600T5 (pl) 2021-03-08
WO2010072691A1 (fr) 2010-07-01
KR101600308B1 (ko) 2016-03-07
PL2379600T3 (pl) 2014-07-31
US8652471B2 (en) 2014-02-18
EP2746294A3 (fr) 2015-01-07
MX2011006501A (es) 2011-07-12
IL213356A0 (en) 2011-07-31
US9574011B2 (en) 2017-02-21
US20130251722A1 (en) 2013-09-26
AU2009331570B2 (en) 2013-10-17
US20190211112A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
FR24C1008I1 (fr) Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire
FR17C1022I2 (fr) Anticorps humains à grande affinité contre pcsk9
ES2590905T8 (es) Inhibidores de la tirosina quinasa de Bruton
BRPI0906025A2 (pt) "aparelho de refrigeração"
BRPI0906085A2 (pt) "aparelho de refrigeração"
BRPI1010909A2 (pt) "inseticida arilpirrolinas"
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
ITTO20080027U1 (it) "apparato di refrigerazione domestico"
FR2908035B1 (fr) Implant interepineux
BRPI0914533A2 (pt) "métodos"
BRPI0819960A2 (pt) "biomaterial e método de preparação do mesmo"
FR2932680B1 (fr) Association de tiliroside et d'un peptide
FI20065482A0 (fi) Vuodesohva
MA30860B1 (fr) Myrtillier denomme "c97-390"
FR2929850B1 (fr) Inhibiteurs de l'enzyme tyrosinage
BRPI0906053A2 (pt) "enzima artificial"
BRPI0910484A2 (pt) esqueletos artificiais de proteína
UA18085S (uk) Шафа спеціальна хірургів для білизни та взуття
TH104914B (th) "ตู้เย็น"
TH100014B (th) "ตู้เย็น"
EE200600022A (et) Varvaste ravi-proflaktiline separaator
TH96258B (th) "แม่เหล็กติดตู้เย็น"
FR2925857B1 (fr) Implant femoral
ES1069987Y (es) "botiquin de primeros auxilios"
ATE522613T1 (de) Genetische modifikation homolaktischer thermophiler bacilli